RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma
• * Metastatic or recurrent disease
• * Not curable by standard therapies
• Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease
• * Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies
• * Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression
• Meets 1 of the following criteria:
• * At least 1 measurable site of disease ≥ 2 cm by radiography
• * Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator
• RAAG12 expression confirmed\* by immunohistochemistry NOTE: \*Not required for patients with colon, pancreatic, or gastric adenocarcinoma
• No evidence of residual or recurrent CNS metastases
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Sex
• Not specified
• Menopausal status
• Not specified
• Performance status
• ECOG 0-1
• Life expectancy
• More than 3 months
• Hematopoietic
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• γ-glutamyl transferase ≤ 2.5 times ULN
• Adequate hepatic function sufficient to undergo study therapy
• Renal
• Creatinine \< 1.5 mg/dL
• Adequate renal function sufficient to undergo study therapy
• Cardiovascular
• No New York Heart Association class III or IV heart disease
• No thrombosis within the past 3 months, including any of the following:
• * Deep vein thrombosis
• * Myocardial infarction
• * Stroke
• Adequate cardiac function sufficient to undergo study therapy
• Pulmonary
• No pulmonary embolism within the past 3 months
• No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis
• Adequate pulmonary function sufficient to undergo study therapy
• Immunologic
• No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks
• No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents
• No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug
• Other
• Amylase and lipase normal
• No other primary malignancy within the past 3 years except for the following:
• * Treated non-melanoma skin cancer
• * Carcinoma in situ of the cervix by biopsy
• * Squamous intraepithelial lesion of the cervix by PAP smear
• * Localized prostate cancer (Gleason score \< 6)
• * Resected melanoma in situ
• No other serious medical condition that would preclude study participation
• No dementia or altered mental status that would preclude giving informed consent
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 3 half-lives since prior monoclonal antibody therapy
• No concurrent vaccinations
• No concurrent prophylactic hematologic growth factors
• Chemotherapy
• At least 4 weeks since prior chemotherapy
• Endocrine therapy
• No concurrent steroids except for the following:
• * Inhaled, ophthalmic, or nasal steroids
• * Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day
• Radiotherapy
• At least 4 weeks since prior radiotherapy
• Surgery
• More than 4 weeks since prior major surgery
• Other
• More than 4 weeks since prior investigational agents
• Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week
• No other concurrent antineoplastic therapy
• No concurrent immunosuppressive medications
• No other concurrent investigational agents
• No concurrent vitamins except those approved by the medical monitor
• * Concurrent daily multivitamin allowed
• Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month prior to study entry